Generic Name: erenumab
Brand Name: TBC
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Manufacturer Requested Reimbursement Criteria1:
For the prevention of migraine in adults with at least 8 migraine days per month who have previously failed at least two migraine preventive therapies due to lack of efficacy, intolerance, or clinical contraindication.
Submission Type: New
Project Status: Pending
Call For Patient Input: July 12, 2018
Patient Input Closed: August 31, 2018
Anticipated Date: August 10, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
headache disorders, nervous system